33. The use according to any one of the previous claims, wherein said medicament further comprises an anti-obesity agent or anti-diabetes agent.

34. The use according to claim 33, wherein said antiobesity agent is lorcaserin.

35. The use according to claim 33, wherein said antiobesity agent is phentermine.

36. The use according to claim 33, wherein said antiobesity agent is a combination of lorcaserin and phentermine.

37. The use according to claim 33, wherein said antiobesity agent is a combination of topiramate and phentermine.

38. The use according to claim 33, wherein said antiobesity agent is a combination of bupropion and naltrexone.

39. The use according to claim 33, wherein said anti-obesity agent or said anti-diabetes agent is co-formulated with said biguanide compound and is to be administered simultaneously in a combined formulation.

40. The use according to claim 39, wherein said combined formulation is provided in the form of a delayed release component coupled with an immediate release component in a unitary dosage form.